<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451451</url>
  </required_header>
  <id_info>
    <org_study_id>109MS302</org_study_id>
    <nct_id>NCT00451451</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis</brief_title>
  <acronym>CONFIRM</acronym>
  <official_title>A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if treatment with BG00012 can decrease the number of MS relapses during a
      certain time period. Other goals of the study are to determine if, over time, BG00012
      treatment can decrease the number of certain types of brain lesions commonly seen in MS
      patients and slow down the time it takes for MS to get worse.

      Other objectives of the study are to determine the safety and tolerability of BG00012, as
      well as the effect it may have on tests and evaluations used to assess MS. Additionally,
      glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects
      approximately 400,000 persons in North America and 365,000 persons in Europe. It is
      predominantly a disease of young adults, primarily women, with disease onset typically
      occurring between the ages of 20 and 40.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized Relapse Rate</measure>
    <time_frame>2 years</time_frame>
    <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee.
The adjusted annualized relapse rate was calculated from a negative binomial regression model , adjusted for baseline Expanded Disability Status Scale (EDSS ) score(≤2.0 versus&gt;2.0), age (&lt;40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of New or Newly Enlarging T2 Hyperintense Lesions</measure>
    <time_frame>2 years</time_frame>
    <description>The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 hyperintense lesion count were calculated from a negative binomial regression model adjusted for region and baseline T2 hyperintense lesion volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New T1 Hypointense Lesions</measure>
    <time_frame>2 years</time_frame>
    <description>The number of new T1 hypointense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T1 hypointense lesion count were calculated from a negative binomial regression model adjusted for region and baseline T1 hypointense lesion volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Relapsed</measure>
    <time_frame>2 years</time_frame>
    <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>2 years</time_frame>
    <description>EDSS is based on a standardized neurological exam and focuses on symptoms that commonly occur in MS. Scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or ≥1.5 point increase in subjects with a baseline EDSS=0, and required that the increase from baseline was confirmed ≥ 12weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1417</enrollment>
  <condition>Relapsing-Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>BG00012 240 mg Twice Daily (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BG00012 240 mg 3 Times Daily (TID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received two placebo capsules orally three times daily (TID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BG00012</intervention_name>
    <arm_group_label>BG00012 240 mg Twice Daily (BID)</arm_group_label>
    <arm_group_label>BG00012 240 mg 3 Times Daily (TID)</arm_group_label>
    <other_name>dimethyl fumarate</other_name>
    <other_name>Tecfidera®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>BG00012 240 mg Twice Daily (BID)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer Acetate</intervention_name>
    <arm_group_label>Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Unless otherwise specified, to be eligible to participate in this study, candidates must
        meet the following eligibility criteria at the time of the randomization:

        Key Inclusion Criteria:

          -  Must have confirmed diagnosis of RRMS according to McDonald criteria #1-4

          -  Must have a baseline EDSS between 0.0 and 5.0, inclusive.

          -  Must have relapsing-remitting disease course.

        Key Exclusion Criteria:

          -  Other chronic disease of immune system, malignancies, urologic, pulmonary,
             gastrointestinal disease

          -  Pregnant or nursing women

        Note: Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meridan</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Souderton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vitebsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lommel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sijsele-Damme</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woluwe</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tuzla</city>
        <state>B&amp;H Federation</state>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banja Luka</city>
        <state>Republic Srpska</state>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarajevo B&amp;H Federation</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osijek</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rijeka</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Moravska</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuressaare</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bayreuth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berg Starnberger</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dusseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Giessen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle (Saale)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schwerin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larisa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Patra</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calicut</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chandigarh</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cochin</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coimbatore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kochi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ludhiana</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Safed</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Skopje</city>
        <country>Macedonia, The Former Yugoslav Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jal</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico DF</city>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico DF</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterray</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kishinev</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guaynabo</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tirgu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tirgu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nis</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gandia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Simferopol</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Bosnia and Herzegovina</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Latvia</country>
    <country>Macedonia, The Former Yugoslav Republic of</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>Kazakhstan</country>
    <country>Lithuania</country>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2007</study_first_submitted>
  <study_first_submitted_qc>March 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2007</study_first_posted>
  <results_first_submitted>May 5, 2014</results_first_submitted>
  <results_first_submitted_qc>May 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2014</results_first_posted>
  <disposition_first_submitted>November 1, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 1, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 5, 2012</disposition_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>relapsing</keyword>
  <keyword>multiple sclerosis</keyword>
  <keyword>oral</keyword>
  <keyword>remitting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>Dimethyl Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were randomized at 205 investigational sites in 28 countries.</recruitment_details>
      <pre_assignment_details>From screening, 1430 eligible subjects were equally randomized. Of these, 1417 subjects received at least one dose of study treatment and comprised the intent-to-treat (ITT) and safety populations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received two placebo capsules orally three times daily (TID)</description>
        </group>
        <group group_id="P2">
          <title>BG00012 240 mg Twice Daily (BID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
        </group>
        <group group_id="P3">
          <title>BG00012 240 mg 3 Times Daily (TID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
        </group>
        <group group_id="P4">
          <title>Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)</title>
          <description>Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="363">363 participants were dosed; 363 participants were randomized</participants>
                <participants group_id="P2" count="359">359 participants were dosed; 362 participants were randomized</participants>
                <participants group_id="P3" count="345">345 participants were dosed; 345 participants were randomized</participants>
                <participants group_id="P4" count="350">350 participants were dosed; 360 participants were randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="278"/>
                <participants group_id="P2" count="284"/>
                <participants group_id="P3" count="273"/>
                <participants group_id="P4" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="58"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons for Not Completing Study</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received two placebo capsules orally three times daily (TID)</description>
        </group>
        <group group_id="B2">
          <title>BG00012 240 mg Twice Daily (BID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
        </group>
        <group group_id="B3">
          <title>BG00012 240 mg 3 Times Daily (TID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
        </group>
        <group group_id="B4">
          <title>Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)</title>
          <description>Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="363"/>
            <count group_id="B2" value="359"/>
            <count group_id="B3" value="345"/>
            <count group_id="B4" value="350"/>
            <count group_id="B5" value="1417"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.9" spread="9.24"/>
                    <measurement group_id="B2" value="37.8" spread="9.35"/>
                    <measurement group_id="B3" value="37.8" spread="9.39"/>
                    <measurement group_id="B4" value="36.7" spread="9.06"/>
                    <measurement group_id="B5" value="37.3" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="250"/>
                    <measurement group_id="B4" value="247"/>
                    <measurement group_id="B5" value="993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="103"/>
                    <measurement group_id="B5" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean Expanded Disability Status Scale (EDSS) score</title>
          <description>The EDSS scores range from 0.0 (normal exam) to 10.0 (death due to MS).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.59" spread="1.170"/>
                    <measurement group_id="B2" value="2.56" spread="1.202"/>
                    <measurement group_id="B3" value="2.52" spread="1.185"/>
                    <measurement group_id="B4" value="2.57" spread="1.223"/>
                    <measurement group_id="B5" value="2.56" spread="1.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of relapses within the previous 3 years</title>
          <units>Number of relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="1.46"/>
                    <measurement group_id="B2" value="2.4" spread="1.27"/>
                    <measurement group_id="B3" value="2.6" spread="1.50"/>
                    <measurement group_id="B4" value="2.4" spread="1.32"/>
                    <measurement group_id="B5" value="2.5" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of relapses within the past 12 months</title>
          <units>Number of relapses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" spread="0.80"/>
                    <measurement group_id="B2" value="1.3" spread="0.63"/>
                    <measurement group_id="B3" value="1.4" spread="0.72"/>
                    <measurement group_id="B4" value="1.4" spread="0.64"/>
                    <measurement group_id="B5" value="1.4" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since first multiple sclerosis (MS) diagnosis</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="5.01"/>
                    <measurement group_id="B2" value="4.9" spread="5.11"/>
                    <measurement group_id="B3" value="4.6" spread="5.23"/>
                    <measurement group_id="B4" value="4.4" spread="4.70"/>
                    <measurement group_id="B5" value="4.7" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean number of Gadolinium(Gd)-enhancing T1-weighted lesions</title>
          <description>This baseline measure could only be assessed in the magnetic resonance imaging (MRI) cohort. The MRI cohort included 681 intent-to-treat (ITT) subjects who were enrolled at sites that participated in the MRI portion of the study and who had MRI data (167 placebo, 169 BG00012 BID, 170 BG00012 TID, and 175 GA). Sites could participate only if their MRI capability was validated by the independent MRI reading center. Approximately 95% of all subjects enrolled at MRI sites participated in the MRI portion of the study.</description>
          <units>Number of Gd enhancing lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="7.71"/>
                    <measurement group_id="B2" value="2.7" spread="6.22"/>
                    <measurement group_id="B3" value="1.9" spread="5.02"/>
                    <measurement group_id="B4" value="2.4" spread="6.81"/>
                    <measurement group_id="B5" value="2.4" spread="6.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annualized Relapse Rate</title>
        <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee.
The adjusted annualized relapse rate was calculated from a negative binomial regression model , adjusted for baseline Expanded Disability Status Scale (EDSS ) score(≤2.0 versus&gt;2.0), age (&lt;40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.</description>
        <time_frame>2 years</time_frame>
        <population>The intent-to-treat (ITT) population was defined as all subjects who were randomized and received at least 1 dose of study treatment. Among subjects who switched to an alternative therapy for multiple sclerosis, all the data before the switch were used for the analysis. In all other subjects, all relapses were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg Twice Daily (BID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg 3 Times Daily (TID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O4">
            <title>Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)</title>
            <description>Participants received Glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Annualized Relapse Rate</title>
          <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee.
The adjusted annualized relapse rate was calculated from a negative binomial regression model , adjusted for baseline Expanded Disability Status Scale (EDSS ) score(≤2.0 versus&gt;2.0), age (&lt;40 versus ≥40 years), region, and the number of relapses in the 1 year prior to enrollment.</description>
          <population>The intent-to-treat (ITT) population was defined as all subjects who were randomized and received at least 1 dose of study treatment. Among subjects who switched to an alternative therapy for multiple sclerosis, all the data before the switch were used for the analysis. In all other subjects, all relapses were included in the analysis.</population>
          <units>Relapses Per Year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="359"/>
                <count group_id="O3" value="345"/>
                <count group_id="O4" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.401" lower_limit="0.329" upper_limit="0.488"/>
                    <measurement group_id="O2" value="0.224" lower_limit="0.179" upper_limit="0.282"/>
                    <measurement group_id="O3" value="0.198" lower_limit="0.156" upper_limit="0.252"/>
                    <measurement group_id="O4" value="0.286" lower_limit="0.232" upper_limit="0.353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New or Newly Enlarging T2 Hyperintense Lesions</title>
        <description>The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 hyperintense lesion count were calculated from a negative binomial regression model adjusted for region and baseline T2 hyperintense lesion volume.</description>
        <time_frame>2 years</time_frame>
        <population>Of the 681 subjects in the MRI cohort, 572 (139 placebo, 140 BG00012 BID, 140 BG00012 TID, 153 GA) had post-baseline T2 hyperintense data &amp; were included in the analysis. Missing data before the use of alternative MS medications &amp; visits after subjects switched to alternative MS medications were imputed with the use of a constant rate assumption.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg Twice Daily (BID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg 3 Times Daily (TID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O4">
            <title>Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)</title>
            <description>Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New or Newly Enlarging T2 Hyperintense Lesions</title>
          <description>The number of new or newly enlarging T2 hyperintense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T2 hyperintense lesion count were calculated from a negative binomial regression model adjusted for region and baseline T2 hyperintense lesion volume.</description>
          <population>Of the 681 subjects in the MRI cohort, 572 (139 placebo, 140 BG00012 BID, 140 BG00012 TID, 153 GA) had post-baseline T2 hyperintense data &amp; were included in the analysis. Missing data before the use of alternative MS medications &amp; visits after subjects switched to alternative MS medications were imputed with the use of a constant rate assumption.</population>
          <units>Number of lesions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="13.5" upper_limit="22.4"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.9" upper_limit="6.6"/>
                    <measurement group_id="O3" value="4.7" lower_limit="3.6" upper_limit="6.2"/>
                    <measurement group_id="O4" value="8.0" lower_limit="6.3" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New T1 Hypointense Lesions</title>
        <description>The number of new T1 hypointense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T1 hypointense lesion count were calculated from a negative binomial regression model adjusted for region and baseline T1 hypointense lesion volume.</description>
        <time_frame>2 years</time_frame>
        <population>Of the 681 subjects in the MRI cohort, 573 (139 placebo,140 BG00012 BID,140 BG00012 TID,154 GA) had post-baseline new T1 hypointense data &amp; were included in the analysis. Missing data before the use of alternative MS medications &amp; visits after subjects switched to alternative MS medications were imputed with the use of a constant rate assumption</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg Twice Daily (BID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg 3 Times Daily (TID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O4">
            <title>Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)</title>
            <description>Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New T1 Hypointense Lesions</title>
          <description>The number of new T1 hypointense lesions at 2 years that developed in each subject compared to baseline assessed on brain magnetic resonance imaging (MRI) scans. The estimates of mean T1 hypointense lesion count were calculated from a negative binomial regression model adjusted for region and baseline T1 hypointense lesion volume.</description>
          <population>Of the 681 subjects in the MRI cohort, 573 (139 placebo,140 BG00012 BID,140 BG00012 TID,154 GA) had post-baseline new T1 hypointense data &amp; were included in the analysis. Missing data before the use of alternative MS medications &amp; visits after subjects switched to alternative MS medications were imputed with the use of a constant rate assumption</population>
          <units>Number of lesions</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
                <count group_id="O2" value="140"/>
                <count group_id="O3" value="140"/>
                <count group_id="O4" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" lower_limit="5.3" upper_limit="9.2"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.3" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.4" lower_limit="1.8" upper_limit="3.2"/>
                    <measurement group_id="O4" value="4.1" lower_limit="3.2" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Relapsed</title>
        <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.</description>
        <time_frame>2 years</time_frame>
        <population>The analysis was based on the ITT population, defined as all subjects who were randomized and received at least 1 dose of study treatment. Among subjects who switched to an alternative therapy for MS, all the data before the switch were used for the analysis. In all other subjects, all relapses were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg Twice Daily (BID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg 3 Times Daily (TID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O4">
            <title>Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)</title>
            <description>Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Relapsed</title>
          <description>A protocol-defined relapse was defined as new or recurrent neurologic symptoms not associated with fever or infection that lasted at least 24 hours, and were separated by at least 30 days from onset of a preceding relapse. All protocol-defined relapses were evaluated by an independent neurologic evaluation committee. The proportion of subjects with a relapse was estimated using the Kaplan-Meier method, which was based on the time-to-first-relapse survival distribution.</description>
          <population>The analysis was based on the ITT population, defined as all subjects who were randomized and received at least 1 dose of study treatment. Among subjects who switched to an alternative therapy for MS, all the data before the switch were used for the analysis. In all other subjects, all relapses were included in the analysis.</population>
          <units>Proportion of subjects,confirmed relapse</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="359"/>
                <count group_id="O3" value="345"/>
                <count group_id="O4" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.410"/>
                    <measurement group_id="O2" value="0.291"/>
                    <measurement group_id="O3" value="0.241"/>
                    <measurement group_id="O4" value="0.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)</title>
        <description>EDSS is based on a standardized neurological exam and focuses on symptoms that commonly occur in MS. Scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or ≥1.5 point increase in subjects with a baseline EDSS=0, and required that the increase from baseline was confirmed ≥ 12weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution</description>
        <time_frame>2 years</time_frame>
        <population>The analysis population consisted of the intent-to-treat (ITT) population (all subjects who were randomized and received at least 1 dose of study treatment) who had a baseline EDSS assessment. Analyses were based on all observed data. Onset of disability progression must begin before a subject switched to alternative MS medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received two placebo capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O2">
            <title>BG00012 240 mg Twice Daily (BID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>BG00012 240 mg 3 Times Daily (TID)</title>
            <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
          </group>
          <group group_id="O4">
            <title>Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)</title>
            <description>Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)</title>
          <description>EDSS is based on a standardized neurological exam and focuses on symptoms that commonly occur in MS. Scores range from 0.0 (normal) to 10.0 (death due to MS). Disability progression was defined as ≥ 1.0 point increase in subjects with a baseline EDSS of ≥1.0, or ≥1.5 point increase in subjects with a baseline EDSS=0, and required that the increase from baseline was confirmed ≥ 12weeks later. The proportion of subjects with confirmed (12-week) disability progression was estimated using the Kaplan-Meier method, which was based on the time-to-first-progression survival distribution</description>
          <population>The analysis population consisted of the intent-to-treat (ITT) population (all subjects who were randomized and received at least 1 dose of study treatment) who had a baseline EDSS assessment. Analyses were based on all observed data. Onset of disability progression must begin before a subject switched to alternative MS medication.</population>
          <units>Proportion of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="363"/>
                <count group_id="O2" value="359"/>
                <count group_id="O3" value="345"/>
                <count group_id="O4" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.169"/>
                    <measurement group_id="O2" value="0.128"/>
                    <measurement group_id="O3" value="0.130"/>
                    <measurement group_id="O4" value="0.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>The safety population consisted of all subjects who received at least 1 dose of study treatment. Safety data were analyzed by actual treatment received. One patient randomly assigned to the BG00012 TID group &amp; included in the group of the ITT population took GA throughout the study and was therefore counted in the GA group of the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received two placebo capsules orally three times daily (TID)</description>
        </group>
        <group group_id="E2">
          <title>BG00012 240 mg Twice Daily (BID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)</description>
        </group>
        <group group_id="E3">
          <title>BG00012 240 mg 3 Times Daily (TID)</title>
          <description>Participants received two 120 mg BG00012 capsules orally three times daily (TID)</description>
        </group>
        <group group_id="E4">
          <title>Total BG00012</title>
          <description>Combined BG00012 240 mg twice daily (BID) dose group and BG00012 240 mg 3 times daily (TID) dose group</description>
        </group>
        <group group_id="E5">
          <title>Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)</title>
          <description>Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="115" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="60" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>MYOCARDITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VESTIBULAR ATAXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>HOLMES-ADIE PUPIL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>DUODENITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>DOUGLAS' ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>H1N1 INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PELVIC INFLAMMATORY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>BORRELIA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PYOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>TRACHEITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>FACIAL BONES FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>LIGAMENT RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>TRAUMATIC HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>EYE INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>HAND FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>LIGAMENT INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>THERAPEUTIC AGENT TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>WHIPLASH INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BETA 2 MICROGLOBULIN URINE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>BREAST NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>CERVIX CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>FIBROMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>THYROID CANCER METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MULTIPLE SCLEROSIS RELAPSE</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>BENIGN INTRACRANIAL HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>MIGRAINE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>OCCIPITAL NEURALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PARTIAL SEIZURES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>RESTLESS LEGS SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>APHASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>ABORTION SPONTANEOUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>GESTATIONAL OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>BIPOLAR I DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>SUICIDE ATTEMPT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>COMPLETED SUICIDE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>BLADDER DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>BLADDER PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>BLADDER DIVERTICULUM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>NEPHROPTOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>BARTHOLIN'S CYST</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>UTERINE HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>NASAL POLYPS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>SOCIAL PROBLEM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>BREAST LUMP REMOVAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>MEDICAL DIET</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>CERVICAL CONISATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>STERILISATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>TURBINECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="332" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="336" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="316" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="652" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="303" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="95" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="91" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="29" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="125" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="91" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ALBUMIN URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PROTEIN URINE PRESENT</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MULTIPLE SCLEROSIS RELAPSE</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="185" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="115" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="98" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>MICROALBUMINURIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>PRURITIS</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="193" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="351"/>
              </event>
              <event>
                <sub_title>HOT FLUSH</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="363"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="359"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="344"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="703"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="351"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The provisions of our agreement are subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Biogen Idec Study Medical Director</name_or_title>
      <organization>Biogen Idec</organization>
      <email>clinicaltrials@biogenidec.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

